No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 40 quarters in the window, leaving 23 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:41:29.759Z. Latest historical point 2022-11-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock was $5.75 as of Oct 6, 2026, 10:40 AM EDT, down 1.79% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -60.4% · 3-year avg -3.4%/yr · 5-year avg -28.3%/yr
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity.
Biotechnology · Norwood, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.21
Revenue Est.
$2.00M
Last Quarter Results
EPS
$-1.81
vs Estimate
$-1.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CRBP | $106.44M | $5.75 | -1.79% | -60.38% | -28.32% | -31.74% | N/A |
| 2BDTX | $106.58M | $1.86 | -4.12% | -49.96% | -24.47% | N/A | vs CRBP |
| 3IMUX | $106.66M | $7.83 | -2.97% | -17.41% | -35.70% | -43.80% | vs CRBP |
| 4CPIX | $107.43M | $7.17 | +1.13% | +172.53% | +25.62% | +5.52% | vs CRBP |
| 5DH | $104.99M | $0.99 | +0.88% | -70.99% | -52.54% | N/A | vs CRBP |
| 6APYX | $109.07M | $2.59 | -0.38% | -10.07% | -28.10% | N/A | vs CRBP |
forward FY estimate
N/A
$0.00
vs Estimate
$1.11M
Consensus Rating
Based on 10 analysts
Average Price Target
$34.02
+492.3% upside
Low
$17.25
Current
$5.75
High
$48.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.60 | $-1.21 | $-0.80 | 7 |
| Quarter ending Dec 2026 | $-1.57 | $-1.32 | $-0.90 | 7 |
| Quarter ending Mar 2027 | $-1.24 | $-1.24 | $-1.24 | 2 |
| Quarter ending Jun 2027 | $-1.27 | $-1.27 | $-1.27 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.59 | $-5.43 | $-3.93 | 8 |
| FY 2027 | $-5.88 | $-5.51 | $-4.93 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.00M | $2.00M | $2.00M | 9 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.00M | $2.00M | $2.00M | 9 |
| FY 2027 | $3.60M | $3.60M | $3.60M | 9 |
